on EURAZEO (EPA:RF)
EURAZEO Leads €29 Million Series B for Germitec
The Nov Santé Actions Non Cotées Fund, managed by Eurazeo, has announced its participation in a €29 million Series B fundraising for Germitec. This investment highlights Eurazeo's commitment to strengthening its presence in the healthcare sector. Germitec, a French MedTech company based in Bordeaux, specializes in High-Level Disinfection solutions for ultrasound probes. Their innovative, chemical-free technology aims to reduce cross-contamination risks in medical environments.
With demand surging in the global disinfection market, Germitec is positioned as a significant player. The company already has a presence in over 40 countries and is targeting the U.S. market, having recently obtained FDA De Novo certification for its Chronos product. CEO Vincent Gardès expressed confidence in capturing the U.S. market opportunities.
This investment marks Eurazeo's third Growth Equity venture with Nov Santé Actions Non Cotées, further expanding their healthcare expertise.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EURAZEO news